IL1B and non-small cell lung carcinoma: Clinical trials for gevokizumab (an allosteric anti–IL-1β antibody) with standard care of anti-cancer therapies for metastatic colorectal, gastroesophageal and renal cancers, FL-101 (a monoclonal anti-IL-1β antibody) for surgically resectable NSCLC, isunakinra (a fusion protein-based inhibitor of the IL-1R containing domains from both IL-1β and IL-1Ra) for solid tumors, and anakinra (an IL-1 receptor antagonist) for hematological malignancies are ongoing.